(Q36283538)

13 August 2017

1 reference

title

Thiazolidinediones and inflammation (English)

1 reference

13 August 2017

0 references

A Consoli

1

1 reference

13 August 2017

E Devangelio

series ordinal

2

1 reference

13 August 2017

publication date

1 January 2005

1 reference

13 August 2017

1 reference

13 August 2017

volume

14

1 reference

13 August 2017

issue

9

1 reference

13 August 2017

page(s)

794-797

1 reference

Nuclear receptors and lipid physiology: opening the X-files

13 August 2017

cites work

1 reference

https://api.crossref.org/works/10.1191%2F0961203305LU2223OA

Peroxisome proliferator-activated receptor gamma and metabolic disease.

21 January 2018

1 reference

https://api.crossref.org/works/10.1191%2F0961203305LU2223OA

21 January 2018

1 reference

https://api.crossref.org/works/10.1191%2F0961203305LU2223OA

Regulation of the Hedgehog and Wingless signalling pathways by the F-box/WD40-repeat protein Slimb

21 January 2018

1 reference

https://api.crossref.org/works/10.1191%2F0961203305LU2223OA

The peroxisome proliferator-activated receptor-gamma is a negative regulator of macrophage activation

21 January 2018

1 reference

https://api.crossref.org/works/10.1191%2F0961203305LU2223OA

Rosiglitazone, a ligand of the peroxisome proliferator-activated receptor-gamma, reduces acute inflammation

21 January 2018

1 reference

https://api.crossref.org/works/10.1191%2F0961203305LU2223OA

Peroxisome proliferator activator receptor-gamma ligands, 15-deoxy-Delta(12,14)-prostaglandin J2 and ciglitazone, reduce systemic inflammation in polymicrobial sepsis by modulation of signal transduction pathways

21 January 2018

1 reference

https://api.crossref.org/works/10.1191%2F0961203305LU2223OA

Evidence for a potent antiinflammatory effect of rosiglitazone

21 January 2018

1 reference

https://api.crossref.org/works/10.1191%2F0961203305LU2223OA

Effect of rosiglitazone treatment on nontraditional markers of cardiovascular disease in patients with type 2 diabetes mellitus

21 January 2018

1 reference

https://api.crossref.org/works/10.1191%2F0961203305LU2223OA

Antidiabetic PPAR gamma-activator rosiglitazone reduces MMP-9 serum levels in type 2 diabetic patients with coronary artery disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1191%2F0961203305LU2223OA

Effect of Rosiglitazone Treatment on Soluble CD40L in Patients With Type 2 Diabetes and Coronary Artery Disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1191%2F0961203305LU2223OA

Antiatherogenic effect of pioglitazone in type 2 diabetic patients irrespective of the responsiveness to its antidiabetic effect

21 January 2018

1 reference

https://api.crossref.org/works/10.1191%2F0961203305LU2223OA

Apoptosis in the rheumatic diseases

21 January 2018

1 reference

https://api.crossref.org/works/10.1191%2F0961203305LU2223OA

15-deoxy-delta(12,14)-PGJ(2) induces synoviocyte apoptosis and suppresses adjuvant-induced arthritis in rats

21 January 2018

1 reference

https://api.crossref.org/works/10.1191%2F0961203305LU2223OA

Functional changes in rheumatoid fibroblast-like synovial cells through activation of peroxisome proliferator-activated receptor gamma-mediated signalling pathway

21 January 2018

1 reference

https://api.crossref.org/works/10.1191%2F0961203305LU2223OA

Peroxisome proliferator-activated receptor-gamma down-regulates chondrocyte matrix metalloproteinase-1 via a novel composite element

21 January 2018

1 reference

https://api.crossref.org/works/10.1191%2F0961203305LU2223OA

10.1191/0961203305LU2223OA

21 January 2018

Identifiers

DOI

1 reference

13 August 2017

1 reference